Goodman Michael Aaron, Arumugam Paritha, Pillis Devin Marie, Loberg Anastacia, Nasimuzzaman Mohammed, Lynn Danielle, van der Loo Johannes Christiaan Maria, Dexheimer Phillip Joseph, Keddache Mehdi, Bauer Thomas Roy, Hickstein Dennis Durand, Russell David William, Malik Punam
Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
J Virol. 2017 Dec 14;92(1). doi: 10.1128/JVI.01639-17. Print 2018 Jan 1.
Strong viral enhancers in gammaretrovirus vectors have caused cellular proto-oncogene activation and leukemia, necessitating the use of cellular promoters in "enhancerless" self-inactivating integrating vectors. However, cellular promoters result in relatively low transgene expression, often leading to inadequate disease phenotype correction. Vectors derived from foamy virus, a nonpathogenic retrovirus, show higher preference for nongenic integrations than gammaretroviruses/lentiviruses and preferential integration near transcriptional start sites, like gammaretroviruses. We found that strong viral enhancers/promoters placed in foamy viral vectors caused extremely low immortalization of primary mouse hematopoietic stem/progenitor cells compared to analogous gammaretrovirus/lentivirus vectors carrying the same enhancers/promoters, an effect not explained solely by foamy virus' modest insertional site preference for nongenic regions compared to gammaretrovirus/lentivirus vectors. Using CRISPR/Cas9-mediated targeted insertion of analogous proviral sequences into the gene and then measuring expression, we demonstrate a sequence-specific effect of foamy virus, independent of insertional bias, contributing to reduced genotoxicity. We show that this effect is mediated by a 36-bp insulator located in the foamy virus long terminal repeat (LTR) that has high-affinity binding to the CCCTC-binding factor. Using our LMO2 activation assay, expression was significantly increased when this insulator was removed from foamy virus and significantly reduced when the insulator was inserted into the lentiviral LTR. Our results elucidate a mechanism underlying the low genotoxicity of foamy virus, identify a novel insulator, and support the use of foamy virus as a vector for gene therapy, especially when strong enhancers/promoters are required. Understanding the genotoxic potential of viral vectors is important in designing safe and efficacious vectors for gene therapy. Self-inactivating vectors devoid of viral long-terminal-repeat enhancers have proven safe; however, transgene expression from cellular promoters is often insufficient for full phenotypic correction. Foamy virus is an attractive vector for gene therapy. We found foamy virus vectors to be remarkably less genotoxic, well below what was expected from their integration site preferences. We demonstrate that the foamy virus long terminal repeats contain an insulator element that binds CCCTC-binding factor and reduces its insertional genotoxicity. Our study elucidates a mechanism behind the low genotoxic potential of foamy virus, identifies a unique insulator, and supports the use of foamy virus as a vector for gene therapy.
γ逆转录病毒载体中的强病毒增强子可导致细胞原癌基因激活和白血病,因此在“无增强子”的自我失活整合载体中需要使用细胞启动子。然而,细胞启动子导致转基因表达相对较低,常常导致疾病表型校正不足。泡沫病毒是一种非致病性逆转录病毒,其衍生的载体与γ逆转录病毒/慢病毒相比,对非基因整合表现出更高的偏好,并且与γ逆转录病毒一样,优先整合在转录起始位点附近。我们发现,与携带相同增强子/启动子的类似γ逆转录病毒/慢病毒载体相比,置于泡沫病毒载体中的强病毒增强子/启动子导致原代小鼠造血干/祖细胞的永生化极低,这种效应不能仅仅用泡沫病毒与γ逆转录病毒/慢病毒载体相比对非基因区域适度的插入位点偏好来解释。利用CRISPR/Cas9介导的将类似前病毒序列靶向插入基因中,然后测量表达,我们证明了泡沫病毒的序列特异性效应,独立于插入偏向,有助于降低基因毒性。我们表明,这种效应由位于泡沫病毒长末端重复序列(LTR)中的一个36碱基对的绝缘子介导,该绝缘子与CCCTC结合因子具有高亲和力结合。使用我们的LMO2激活试验,当从泡沫病毒中去除该绝缘子时,表达显著增加,而当将该绝缘子插入慢病毒LTR中时,表达显著降低。我们的结果阐明了泡沫病毒低基因毒性的潜在机制,鉴定了一种新型绝缘子,并支持将泡沫病毒用作基因治疗载体,特别是在需要强增强子/启动子的情况下。了解病毒载体的基因毒性潜力对于设计安全有效的基因治疗载体很重要。已证明不含病毒长末端重复序列增强子的自我失活载体是安全的;然而,来自细胞启动子的转基因表达通常不足以实现完全的表型校正。泡沫病毒是一种有吸引力的基因治疗载体。我们发现泡沫病毒载体的基因毒性明显更低,远低于根据其整合位点偏好所预期的水平。我们证明泡沫病毒长末端重复序列包含一个与CCCTC结合因子结合并降低其插入基因毒性的绝缘子元件。我们的研究阐明了泡沫病毒低基因毒性潜力背后的机制,鉴定了一种独特的绝缘子,并支持将泡沫病毒用作基因治疗载体。